Prevalence of dyslipidemia, treatment rate and its control among patients with type 2 diabetes mellitus in Northwest China: a cross-sectional study

Abstract

Background The prevalence of cardiovascular disease (CVD) is high in China, especially in Northwest China, and dyslipidemia in diabetes is a major factor at risk for CVD. The dyslipidemia prevalence, treatment and control among type 2 diabetes mellitus (T2DM) patients in Northwest China were investigated. Methods In the cross-sectional retrospective research, 1386 medical records of T2DM patients were collected from the Endocrine Department of Tangdu Hospital. And patients’ age, sex, diabetes duration, glycated hemoglobin (HbA1c), complications, lipid levels, and drug use were recorded. The patient characteristics, lipid level and lipid-lowering therapy were analyzed. Results In this study, the dyslipidemia prevalence among T2DM patients was 87.7%, the treatment rate was 68.0%. The overall control rate of low-density lipoprotein cholesterol (LDL-C) was 43.1%, and control rates reached 52.7% for high-risk subjects and 36.1% for very high-risk subjects. The overall control rate of non-high-density lipoprotein cholesterol (non-HDL-C) was 19.8%. HbA1c (%) ≥ 7 was indicated as a major factor predicting failure of LDL-C and non-HDL-C control [odds ratio (OR) 1.521; 2.206, 95% confidence interval (CI) 1.154–2.005; 1.583–3.076)]. Conclusion Among patients with T2DM, it is high prevalence of dyslipidemia and low rate of treatment and control, and higher HbA1c level is the main factor for poor lipid control. It calls for more efforts to promote early screening, prevention and treatment of dyslipidemia for patients, thereby reducing the risk of CVD.

Decreasing trend of blood lipid profile in type 2 diabetes: Not a promising change in HDL-C, a serial cross-sectional study

“…Studies on achieving ABC goals in diabetes have focused primarily on LDL-C control [ 54 ]. The overall control rate of LDL-C and non-HDL-C among patients with T2D in China has been reported at 43.1% and 19.8%, respectively [ 55 ]. Among patients with T2D in Iran, the achievement of LDL-C ≤100 mg/dl was 48.1% [ 56 ].…”

Association of the systemic immuno-inflammation index, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio with diabetic microvascular complications

“…T2DM, hypertension, and hyperlipidemia were diagnosed by endocrinologists based on the latest guidelines ( 2 , 12 , 20 ), as described in detail in our previous articles ( 21 , 22 ). The diagnosis of diabetic microvascular complications is firstly caused by diabetes, excluding the other primary causes.…”

High triglyceride levels increase the risk of diabetic microvascular complications: a cross-sectional study

“…Although there have been many studies correlating diabetic microvascular complications with lipid profiles, the findings have been highly debated. In addition, previous research from our group found that the dyslipidemia rate is very high in patients with diabetic complications [ 9 ]. However, it is unclear which lipid profiles have a greater impact on diabetic complications.…”